No Data
Daga Weikang: Report for the third quarter of 2024
Vicom Ltd (301126.SZ): Its subsidiary, Jiachen Hospital, is actively promoting the application for human assisted reproduction license qualification.
Gelonghui October 11th | Dajia vicom ltd (301126.SZ) stated at an investor relations event that its subsidiary, Jiachen hospital, is actively pursuing the application for human assisted reproduction license qualification. Due to the high barriers of assisted reproduction technology, lengthy licensing application processes, and strict approval standards, there is uncertainty about the prospects of the company's continued assisted reproduction business.
Vicom Ltd (301126.SZ): invested 10 million yuan to establish a wholly-owned subsidiary Vicom Ltd Regenerative Medicine Research Institute.
On September 27, Gelonghui announced that in order to further meet the needs of its global strategy, enhance the company's market competitiveness, the company used its own funds to set up a wholly-owned subsidiary, Hunan Dajiaweikang Regenerative Medical Research Institute Co., Ltd. (hereinafter referred to as "Dajiaweikang Regenerative Medical Research Institute"). Recently, the Dajiaweikang Regenerative Medical Research Institute has completed the industrial and commercial registration and obtained the "Business License" issued by the Changsha County Market Supervision Administration. The establishment of this wholly-owned subsidiary will help further strengthen the company's development in the field of medical services and enhance the company's leading position in this area.
Daga Weikang: 2024 Semi-Annual Report Summary
Daga Weikang: 2024 Semi-Annual Report
Dajia Vicom (301126.SZ): net income for the first half of the year was 31.834 million yuan, a year-on-year increase of 75.04%.
On August 29th, Ge Long Hui reported its semi-annual report for 2024, with operating revenue of 2.6 billion yuan, a year-on-year growth of 46.95%; net profit attributable to shareholders of the listed company of 31.834 million yuan, a year-on-year growth of 75.04%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of 31.1106 million yuan, a year-on-year growth of 90.32%; and basic earnings per share of 0.15 yuan.
Investors Still Aren't Entirely Convinced By Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Revenues Despite 28% Price JumpNo Data
No Data
